Switch theme
Sign up to access all valuation multiples
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
2019
167
Last FY Revenue n/a
LTM EBITDA -$167M
-$92.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cargo Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$167M.
In the most recent fiscal year, Cargo Therapeutics achieved revenue of n/a and an EBITDA of -$160M.
Cargo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cargo Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$167M | XXX | -$160M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$173M | XXX | -$187M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$155M | XXX | -$168M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cargo Therapeutics's stock price is $4.
Cargo Therapeutics has current market cap of $196M, and EV of -$92.4M.
See Cargo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$92.4M | $196M | XXX | XXX | XXX | XXX | $-3.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cargo Therapeutics has market cap of $196M and EV of -$92.4M.
Cargo Therapeutics's trades at n/a EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Cargo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cargo Therapeutics has a P/E ratio of -1.3x.
See valuation multiples for Cargo Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $196M | XXX | $196M | XXX | XXX | XXX |
| EV (current) | -$92.4M | XXX | -$92.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCargo Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Cargo Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cargo Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cargo Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cargo Therapeutics acquired XXX companies to date.
Last acquisition by Cargo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cargo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cargo Therapeutics founded? | Cargo Therapeutics was founded in 2019. |
| Where is Cargo Therapeutics headquartered? | Cargo Therapeutics is headquartered in United States of America. |
| How many employees does Cargo Therapeutics have? | As of today, Cargo Therapeutics has 167 employees. |
| Who is the CEO of Cargo Therapeutics? | Cargo Therapeutics's CEO is Mr. Anup Radhakrishnan. |
| Is Cargo Therapeutics publicy listed? | Yes, Cargo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cargo Therapeutics? | Cargo Therapeutics trades under CRGX ticker. |
| When did Cargo Therapeutics go public? | Cargo Therapeutics went public in 2023. |
| Who are competitors of Cargo Therapeutics? | Similar companies to Cargo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cargo Therapeutics? | Cargo Therapeutics's current market cap is $196M |
| Is Cargo Therapeutics profitable? | Yes, Cargo Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cargo Therapeutics? | Cargo Therapeutics's last 12 months EBITDA is -$167M. |
| What is the current EV/EBITDA multiple of Cargo Therapeutics? | Current EBITDA multiple of Cargo Therapeutics is 0.6x. |
| What is the current FCF of Cargo Therapeutics? | Cargo Therapeutics's last 12 months FCF is -$125M. |
| What is the current EV/FCF multiple of Cargo Therapeutics? | Current FCF multiple of Cargo Therapeutics is 0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
